ArticlePloS one2025
Quantifying the impacts of volume-based procurement policy on spatial accessibility of antidepressants via generic substitution: A four-city cohort study using drug sales data.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of China's National Volume-Based Procurement policy exclusively for insulin on the volume, expenditure and price: an interrupted time series analysis in Guangdong Province.Frontiers in public health · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the spatial accessibility and inequality of antidepressants and its correlation with VBP (Volume-based procurement) policy using procurement data from four representative Chinese cities between 2018 and 2020.
methodsThe least-cost-path algorithm was employed to calculate travel time from each population point to the nearest medical institution. Gini coefficient and Theil index were utilized to measure accessibility and inequality. OLS (Ordinary Least Squares) and mediation analysis were used to investigate potential statistical relationships.
resultsUnder the influence of the VBP policy, we observed varying degrees of growth in the procurement volumes of two antidepressants across different cities (Escitalopram: Beijing 30.3%, Shanghai 26.2%, Ningbo 37.4%, Harbin 25.7%; Paroxetine: Beijing 28.2%, Shanghai 1.2%, Ningbo 50.2%, Harbin 590.5%). The increase in the procurement volumes of antidepressants across cities was primarily driven by generic drugs (Escitalopram: Beijing 159.8%, Shanghai 75.0%, Ningbo 146.4%, Harbin 146.3%; Paroxetine: Beijing 67.3%, Shanghai 4.9%, Ningbo 58.0%, Harbin 15,758.3%). In the results on spatial inequality, we observed annual improvements across all cities, with more pronounced progress in economically underdeveloped regions (Escitalopram: Gini in Harbin decreased by 10.6%; Paroxetine: Gini in Harbin decreased by 32.6%). In Beijing, the substitution of generic escitalopram was found to be a partial mediating factor in the improvement of spatial inequality (ACME = -0.00, p-value = 0.01; ADE = -0.00, p-value = 0.02). In Harbin, the substitution of generic paroxetine was identified as a complete mediating factor for spatial inequality (ACME = -0.04, p-value = 0.01; ADE = 0.01, p-value = 0.14).
conclusionsThis study found that the spatial accessibility and inequality of antidepressant medications gradually improved under the influence of the VBP policy. These improvements can be partially attributed to the substitution of generic drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.